This is the first study to demonstrate that high CD8+ TIL levels and CD8/FOXP3 ratio in residual tumors could accurately predict the better clinical outcome in TNBC patients with non-pCR following NAC and that the changes of these parameters in breast cancer tissues following NAC were also significantly associated with eventual clinical outcome in TNBCs. This evidence concerns the gene CD8A and breast cancer.